全文获取类型
收费全文 | 457篇 |
免费 | 21篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 10篇 |
基础医学 | 45篇 |
口腔科学 | 15篇 |
临床医学 | 34篇 |
内科学 | 64篇 |
皮肤病学 | 7篇 |
神经病学 | 82篇 |
特种医学 | 35篇 |
外科学 | 81篇 |
综合类 | 37篇 |
预防医学 | 21篇 |
眼科学 | 4篇 |
药学 | 17篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 1篇 |
2022年 | 4篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 3篇 |
2018年 | 10篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 17篇 |
2014年 | 20篇 |
2013年 | 23篇 |
2012年 | 28篇 |
2011年 | 29篇 |
2010年 | 22篇 |
2009年 | 17篇 |
2008年 | 20篇 |
2007年 | 22篇 |
2006年 | 24篇 |
2005年 | 26篇 |
2004年 | 24篇 |
2003年 | 17篇 |
2002年 | 12篇 |
2001年 | 18篇 |
2000年 | 12篇 |
1999年 | 16篇 |
1998年 | 13篇 |
1997年 | 8篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 11篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 3篇 |
排序方式: 共有479条查询结果,搜索用时 15 毫秒
471.
472.
473.
474.
Salsone M Bagnato A Novellino F Cascini GL Paglionico S Cipullo S Morelli M Pugliese P Nicoletti G Messina D Condino F Arabia G Morgante L Quattrone A 《Parkinsonism & related disorders》2009,15(5):365-369
Freezing of gait (FOG) generally occurs as a late manifestation of Parkinson's Disease (PD). FOG, however, can present in isolation, constituting the so-called "Primary Progressive Freezing Gait"(PPFG). Myocardial (123)Metaiodiobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac nerve terminals. MIBG uptake reflects sympathetic system integrity, and reduced myocardial uptake of the tracer has been observed in nearly all patients with PD. We investigated MIBG uptake in 7 patients with PPFG, 14 patients with mild PD, and 6 patients with advanced PD and FOG (PD-FOG), and 18 control subjects. Our study shows that myocardial MIBG uptake was normal in all patients with PPFG (H/M ratio: mean+/-SD, 1.85+/-0.11 early; 1.71+/-0.15 delayed) and in the controls (H/M ratio: mean+/-SD, 1.94+/-0.18 early; 2.02+/-0.19 delayed) whereas it was markedly decreased in the patients with mild and advanced PD (H/M ratio: mean+/-SD, PD: 1.17+/-0.02 early; 1.16+/-0.02 delayed; PD-FOG: 1.22+/-0.10 early; 1.08+/-0.06 delayed). Our findings demonstrate that cardiac sympathetic denervation did not occur in patients with PPFG, confirming that PPFG and PD are distinct diseases. 相似文献
475.
Clara Maria Gonalves de Faria Heloisa Ciol Vanderlei Salvador Bagnato Sebastio Pratavieira 《Biomedical optics express》2021,12(7):3902
Photobiomodulation therapy (PBMT) uses light to stimulate cells. The molecular basis of the effects of PBMT is being unveiled, but it is stated that the cytochrome-c oxidase enzyme in mitochondria, a photon acceptor of PBMT, contributes to an increase in ATP production and modulates the reduction and oxidation of electron carriers NADH and FAD. Since its effects are not fully understood, PBMT is not used on tumors. Thus, it is interesting to investigate if its effects correlate to mitochondrial metabolism and if so, how it could be linked to the optical redox ratio (ORR), defined as the ratio of FAD/(NADH + FAD) fluorescences. To that end, fibroblasts (HDFn cell line) and oral squamous cell carcinoma (SCC-25 cell line) were irradiated with a light source of 780 nm and a total dose of 5 J/cm2, and imaged by optical microscopy. PBMT down-regulated the SCC-25 ORR by 10%. Furthermore, PBMT led to an increase in ROS and ATP production in carcinoma cells after 4 h, while fibroblasts only had a modest ATP increase 6 h after irradiation. Cell lines did not show distinct cell cycle profiles, as both had an increase in G2/M cells. This study indicates that PBMT decreases the redox state of oral cancer by possibly increasing glycolysis and affects normal and tumor cells through distinct pathways. To our knowledge, this is the first study that investigated the effects of PBMT on mitochondrial metabolism from the initiation of the cascade to DNA replication. This is an essential step in the investigation of the mechanism of action of PBMT in an effort to avoid misinterpretations of a variety of combined protocols. 相似文献
476.
477.
The development of neutralising antibodies (NABs), or neutralising activity in the absence of NABs, is a potential complication of therapy with interferon (IFN)-beta for patients with multiple sclerosis, limiting therapeutic efficacy. Discontinuation of IFN-beta therapy in patients found to have sustained titres of NABs > 1:100 over an interval of 3 - 6 months has been recently proposed as a Level A recommendation. The extent to which NABs are causative, rather than an epiphenomenon, in determining drug failure has been a matter of numerous investigations and is still controversial. Thus, further studies are warranted for determining the role that NABs may play in reducing the response to the drug. In particular, the effects of NABs in reducing the efficacy of IFN-beta therapy beyond clinical relapse rate and lesion load on conventional imaging are not as yet fully understood. 相似文献
478.
479.